The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

NCT02978547 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Resectable Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Metformin Hydrochloride 500Mg Tablet

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]
[object Object]